Tag Archives: Piper Sandler
Piper Sandler Reaffirms Their Overweight Rating on AVEO Pharma (AVEO)
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating on AVEO Pharma (NASDAQ: AVEO) on June 11 and set a price target of $26.00. The company’s shares closed last Wednesday at $4.66. The word on The Street in general, suggests
Piper Sandler Reiterates Overweight on Aravive Shares, Sees 449% Upside For The Stock
In a research report issued on Monday, Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating on Aravive (NASDAQ:ARAV)with a price target of $31, which implies an upside of 449% from current levels. According to TipRanks.com, which measures analysts’ and
Northland Securities Reaffirms Their Buy Rating on Piper Sandler (PIPR)
In a report issued on July 31, Michael Grondahl from Northland Securities maintained a Buy rating on Piper Sandler (PIPR – Research Report), with a price target of $70.00. The company’s shares closed last Friday at $61.91. According to TipRanks.com,
Nucana (NCNA) Receives an Overweight from Piper Sandler
In a report issued on May 25, Joseph Catanzaro from Piper Sandler reiterated an Overweight rating on Nucana (NASDAQ: NCNA), with a price target of $15.00. The company’s shares closed last Wednesday at $5.18. The word on The Street in
Piper Sandler Reiterates Overweight on Optinose Shares, Sees 313% Upside For The Stock
In a research report released on Wednesday, Piper Sandler analyst David Amsellem reiterated an Overweight rating on Optinose (NASDAQ:OPTN)with a price target of $19, which represents a potential upside of 313% from where the stock is currently trading. According to
Piper Sandler Reaffirms Their Overweight Rating on Matinas BioPharma (MTNB)
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating on Matinas BioPharma (NYSE MKT: MTNB) on June 30 and set a price target of $1.50. The company’s shares closed last Saturday at $0.71, close to its 52-week low of $0.49.
